Children's Oncology Group

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Children's Oncology Group sits in the top decile of US sponsors by registered trial count (#104 of 15,742 sponsors by registered trial count).

342 total trials 33 currently recruiting 260 completed top decile by trial count

Children's Oncology Group: 342 sponsored US clinical trials, 33 recruiting.

Children's Oncology Group sponsors 342 registered US clinical trials on ClinicalTrials.gov, 33 of them currently recruiting, and 260 completed. 103 of these trials are in Phase 3-4 (later-stage) and 128 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Leukemia, with 12 trials.

Top-decile sponsor footprint

Children's Oncology Group ranks in the top decile of sponsors by registered trial count (#104 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

B 88/100

260 of 262 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (99.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

342 total, page 3 of 7

COMPLETED

Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

NCT01793233
COMPLETED Phase 1

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

NCT01606878
COMPLETED Phase 1

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

NCT01798004
COMPLETED Phase 3

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

NCT01503515
COMPLETED

Biomarker Differences in Samples From Patients With Undifferentiated Sarcomas

NCT01802125
COMPLETED

Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma

NCT01876303
COMPLETED

Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia

NCT01642121
COMPLETED

Biomarkers in Patients With Advanced Rhabdomyosarcoma

NCT01668095
COMPLETED

Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia

NCT01642069
COMPLETED Phase 2

Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

NCT01602666
COMPLETED

Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients

NCT01623856
COMPLETED

Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia

NCT01625143
COMPLETED

Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma

NCT01609803
COMPLETED

Studying Mechanisms of Radiation Therapy Resistance in Samples From Younger Patients With Rhabdomyosarcoma

NCT01626170
COMPLETED

Studying Biomarkers in Urine Samples From Younger Patients With Wilms Tumor

NCT01614808
COMPLETED

Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia

NCT01576185
COMPLETED NA

Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents

NCT01556256
COMPLETED

Studying Chromosomes in Samples From Younger Patients With Neuroblastoma

NCT01589341
COMPLETED

Study of Tumor Samples From Patients With Ependymoma Treated on the Children's Oncology Group ACNS0121 Trial

NCT01407744
COMPLETED

Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia

NCT01540578
COMPLETED Phase 1

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

NCT01175356
COMPLETED

Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma

NCT01496573
COMPLETED

Biomarkers in Samples From Younger Patients With Wilms Tumor

NCT01493817
COMPLETED

DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings

NCT01434355
COMPLETED Phase 3

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation

NCT01371656
COMPLETED Phase 2

Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

NCT01334515
COMPLETED

Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma

NCT01374672
COMPLETED

Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma

NCT01358617
COMPLETED Phase 1

Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

NCT01273090
COMPLETED Phase 3

Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia

NCT01307579
COMPLETED

Biomarkers in Tissue Samples From Young Patients With Liver Cancer

NCT01336881
COMPLETED Phase 3

Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant

NCT01305200
COMPLETED Phase 2

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

NCT01154816
COMPLETED Phase 3

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

NCT01231906
COMPLETED Phase 1

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

NCT01164163
COMPLETED

Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT01142427
COMPLETED

DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma

NCT01190943
COMPLETED

Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia

NCT01150669
COMPLETED Phase 3

Collection of Bone Marrow From Donors Treated With or Without Filgrastim

NCT01149096
COMPLETED

Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor

NCT01118078
COMPLETED

Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia

NCT01076569
COMPLETED

Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma

NCT01807143
COMPLETED Phase 3

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

NCT01026220
COMPLETED

Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia

NCT01024127
COMPLETED

Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas

NCT01807052
COMPLETED

Gene Analysis in Studying Susceptibility to Wilms Tumor

NCT01808079
COMPLETED Phase 1

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

NCT00939770
COMPLETED

Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia

NCT01146223
COMPLETED Phase 1

Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

NCT01048892
COMPLETED

Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01146210
← Previous Page 3 of 7 Next →

Phase Distribution

PhaseTrial count
Phase 1 53
Phase 2 75
Phase 3 103

Therapeutic Areas

Leukemia 12
Neuroblastoma 8
Acute Lymphoblastic Leukemia 8
Malignant Solid Neoplasm 7
Lymphoma 6
Childhood Acute Lymphoblastic Leukemia in Remission 5
Localized Resectable Neuroblastoma 5
Unspecified Childhood Solid Tumor, Protocol Specific 5
Sarcoma 5
Hematopoietic and Lymphatic System Neoplasm 5

What is open in the Children's Oncology Group pipeline

33 recruiting of 342 indexed (10% open); 260 completed (76%).

Phase mix: 103 late (III/IV) vs 128 early (I/II) (balanced across stages).

Top condition: Leukemia (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Children's Oncology Group: open-pipeline peers nationwide

Peers matched on 342 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Children's Oncology Group sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 5%10%15%20%25% Total trials Recruiting share Children's Oncology GroupNational Institute of Mental Health (NIMH)Ohio State University Comprehensive Cancer CenterMontefiore Medical CenterCedars-Sinai Medical CenterChildren's Hospitals and Clinics of MinnesotaCytokineticsSanofiJoslin Diabetes Center
Children's Oncology Group sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Children's Oncology Group sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 342 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Children's Oncology Group page

342 registered trials is a research-attention snapshot, not an endorsement of Children's Oncology Group or any single study.

  • 33 of Children's Oncology Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Leukemia is the condition Children's Oncology Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Leukemia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Children's Oncology Group pipeline card: 342 registered trials from official public datasets.Report a data error.